Galapagos Archives

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a…

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

biotech stock price euronext genmab argenx

News and Trends 25 May 2021

Delayed IPOs and Market Drops Batter Biotech Stocks

Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic…

May 25, 2021 - 6 minutesmins - By Jonathan Smith

News and Trends 4 Mar 2021

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. Yet the pair claim to be well capitalized…

March 4, 2021 - 4 minutesmins - By Victor Kotsev

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 5 Oct 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What does this signal for Galapagos, Gilead, and other biotechs working…

October 5, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 29 Oct 2019

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing…

October 29, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary…

July 15, 2019 - 2 minutesmins - By Jonathan Smith

Expert Advice 8 Jun 2019

Why Sticking to Your Beliefs is Important for Biotech Success

Galapagos is an undeniable success story. Set up in 1999, it is now one of the largest and most successful biotechs in Europe. A key driving force behind the company…

June 8, 2019 - 11 minutesmins - By Helen Albert

Best in Biotech 2 Apr 2019

The 8 Best Biotech Companies in Europe’s History

We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today.…

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20…

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 23 Oct 2018

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

What does it take to be a successful biotech entrepreneur? I put this and other similar questions to Dinko Valerio, a highly experienced Dutch geneticist turned serial entrepreneur and investor.…

October 23, 2018 - 8 minutesmins - By Helen Albert

News and Trends 20 Feb 2018

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody…

February 20, 2018 - 3 minutesmins - By Alexander Burik

In Depth 23 Jan 2018

Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?

Although biotech may seem like an industry that has only just gotten started, it was already up and running before the turn of the century. We took a look back…

January 23, 2018 - 10 minutesmins - By Alex Dale

News and Trends 8 Jan 2018

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies…

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 26 Dec 2017

Interviews, Reviews and Tops: Our Best Biotech Articles from 2017

We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list…

December 26, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 22 Nov 2017

Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout

Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a Phase I trial. Galapagos is a clinical-stage biotech developing small molecule medicines for a…

November 22, 2017 - 3 minutesmins - By Alex Dale

Interview 25 Sep 2017

Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model

Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It…

September 25, 2017 - 10 minutesmins - By Evelyn Warner

galapagos glpg1690 idiopathic pulmonary fibrosis

More News! 10 Aug 2017

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

Galapagos' GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in…

August 10, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Jul 2017

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib's clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The…

July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 19 Apr 2017

Galapagos Shoots Past its IPO in a New Public Round of €315M

After its record €277 IPO on Nasdaq in 2015, Galapagos announced the pricing of its new US public offering at a massive €315M ($338M). Galapagos is clinging to its position as one…

April 19, 2017 - 2 minutesmins - By Melanie De Almeida

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering